Reports Q3 revenue $319.946M, consensus $314.28M. “We made meaningful progress during the quarter with PYLARIFY and DEFINITY in our commercial portfolio, and with PNT2002 and MK-6240 in our pipeline,” said Mary Anne Heino, Chief Executive Officer of Lantheus. “We believe that our unique capabilities, commitment to innovation and excellence, and growing pipeline supports our position as the leading radiopharmaceutical-focused company.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LNTH:
- Lantheus Reports Third Quarter 2023 Financial Results
- Lantheus price target lowered to $100 from $110 at Truist
- William Blair biotech analyst to hold an analyst/industry conference call
- Lantheus program validated by Point Biopharma buyout, says Mizuho
- Eli Lilly deal for Point puts radiopharma names in spotlight
Questions or Comments about the article? Write to editor@tipranks.com